Needham Reiterates Buy on Sarepta Therapeutics, Maintains $185 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a 'Buy' rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $185.
August 04, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Sarepta Therapeutics and maintained a price target of $185.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a high price target indicates strong confidence in the company's performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100